<DOC>
	<DOCNO>NCT00000699</DOCNO>
	<brief_summary>To determine safety effectiveness treatment ribavirin ( RBV ) plus isoprinosine ( INPX ) prevent development AIDS patient infect AIDS virus ( HIV ) . Also determine maximal dose RBV tolerate HIV-infected patient RBV give INPX . The patient may may generalize lymphadenopathy syndrome ( LAS ) . RBV prevent development AIDS HIV-infected patient LAS INPX stimulate immune system patient infected HIV . The immune system fight infection human body , HIV attack T cell important part immune system . Reports individual case treat RBV INPX suggest clinical improvement occur HIV-infected patient , reliable information safety effectiveness drug combination patient .</brief_summary>
	<brief_title>A Phase I/II Trial Ribavirin ( With Escalation ) + Isoprinosine Asymptomatic HIV-Viremic Patients</brief_title>
	<detailed_description>RBV prevent development AIDS HIV-infected patient LAS INPX stimulate immune system patient infected HIV . The immune system fight infection human body , HIV attack T cell important part immune system . Reports individual case treat RBV INPX suggest clinical improvement occur HIV-infected patient , reliable information safety effectiveness drug combination patient . All patient take INPX capsule 4 time day RBV capsule 2 3 time day . The first group patient take dose RBV show effective earlier trial subsequent group take high dos toxic effect occur . The planned treatment period 3 month , treatment may allow patient show improvement . Blood sample take arm vein use evaluate possible change patient 's immune system , toxic effect might detect blood possible change presence HIV blood .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Inosine Pranobex</mesh_term>
	<criteria>Inclusion Criteria It must possible culture HIV peripheral blood lymphocytes 2 consecutive screening within 2 month start treatment . Concurrent Medication : Allowed : Systemic medication list Exclusion Concurrent Medications field consider necessary patient 's medical management would interfere study may use , use must document . Exclusion Criteria Concurrent Medication : Excluded : Systemic steroid . Cytotoxic immunosuppressive medication . Any systemic experimental antiHIV drug dideoxycytidine ( ddC ) , foscarnet , ribavirin , isoprinosine , zidovudine ( AZT ) . Any medication felt immunomodulatory felt exhibit significant hepatotoxicity hematologic renal toxicity study investigator . Prior Medication : Excluded within 6 week study entry : Systemic steroid . Cytotoxic immunosuppressive medication . Any systemic experimental antiHIV drug dideoxycytidine ( ddC ) , foscarnet , ribavirin , isoprinosine , zidovudine ( AZT ) . Any medication felt immunomodulatory felt exhibit significant hepatotoxicity hematologic renal toxicity study investigator . Current active infection , know cardiac disease , prior history one following : Gout , uric acid urolithiasis , uric acid nephrolithiasis , renal dysfunction . Neoplasms : Other locally treat basal squamous carcinoma . Cardiovascular : Myocardial infarction , cardiac arrhythmia , cardiomyopathy , congestive heart failure . Past current history CDCdefined AIDS include HIV encephalopathy HIV waste syndrome . Constitutional symptom ( CDC Group IVA ) , neurologic symptom ( CDC Group IVB ) , prior current nonAIDS define secondary infectious disease ( CDC Group IVC2 ) . Grade 1 impairment 2 item ACTG Micro NeuroAIDS Assessment . Active drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>Ribavirin</keyword>
	<keyword>Inosine Pranobex</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>